Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: Evidence for the role of adenosine A2 receptors

Purinergic Signalling

Volumn 8, Issue 4, 2012, Pages 693-704

  da Rocha Lapa, Fernanda ^a   da Silva, Morgana Duarte ^b   de Almeida Cabrini, Daniela ^a   Santos, Adair R S ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Adenosine; Adenosine receptors; Carrageenan; Inosine; Pleurisy

Indexed keywords

2 [4 (2 CARBOXYETHYL) PHENETHYLAMINO] ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4[2 [7 AMINO 2 (2 FURYL) 1, 2, 4 TRIAZOLO [2, 3 A] [1, 3, 5] TRIAZIN 5 YLAMINO] ETHYL] PHENOL; ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; CARRAGEENAN; EVANS BLUE; FLAVINE MONONUCLEOTIDE; INOSINE; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL MIGRATION; CONTROLLED STUDY; FEMALE; INFLAMMATION; LEUKOCYTE COUNT; MONONUCLEAR CELL; MOUSE; NEUTROPHIL; NONHUMAN; PLEURA FLUID; PLEURISY;

ADENOSINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; INOSINE; LEUKOCYTES; MICE; PLEURISY; PURINE NUCLEOSIDES; RECEPTORS, ADENOSINE A2;

EID: 84867888323     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-012-9299-2     Document Type: Article

References (59)

1. Hasko G, Sitkovsky MV, Szabo C (2004) Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25(3): 152-157. doi: 10. 1016/j. tips. 2004. 01. 006S0165614704000239.
2. Livingston M, Heaney LG, Ennis M (2004) Adenosine, inflammation and asthma-a review. Inflamm Res 53(5): 171-178. doi: 10. 1007/s00011-004-1248-2.
3. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP (2003) Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 198(5): 783-796. doi: 10. 1084/jem. 20030891jem. 20030891.
4. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3): 413-492.
5. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53(4): 527-552.
6. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR (2006) Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 116(8): 2173-2182. doi: 10. 1172/JCI27303.
7. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC (2006) Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112(2): 358-404. doi: 10. 1016/j. pharmthera. 2005. 04. 013.
8. Schneider L, Pietschmann M, Hartwig W, Marcos SS, Hackert T, Gebhard MM, Uhl W, Buchler MW, Werner J (2006) Inosine reduces microcirculatory disturbance and inflammatory organ damage in experimental acute pancreatitis in rats. Am J Surg 191(4): 510-514. doi: 10. 1016/j. amjsurg. 2005. 09. 009.
9. Cronstein BN (1994) Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76(1): 5-13.
10. Wakai A, Wang JH, Winter DC, Street JT, O'Sullivan RG, Redmond HP (2001) Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation. Shock 15(4): 297-301.
11. Kaufmann I, Hoelzl A, Schliephake F, Hummel T, Chouker A, Lysenko L, Peter K, Thiel M (2007) Effects of adenosine on functions of polymorphonuclear leukocytes from patients with septic shock. Shock 27(1): 25-31. doi: 10. 1097/01. shk. 0000238066. 00074. 90.
12. El-Hashim AZ, Abduo HT, Rachid OM, Luqmani YA, Al Ayadhy BY, Alkhaledi GM (2009) Intranasal administration of NECA can induce both anti-inflammatory and pro-inflammatory effects in BALB/c mice: evidence for A 2A receptor sub-type mediation of NECA-induced anti-inflammatory effects. Pulm Pharmacol Ther 22(3): 243-252. doi: 10. 1016/j. pupt. 2008. 12. 012.
13. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G, Kastsiuchenka O, Duranti E, Virdis A, Vassalle C, La Motta C, Mugnaini L, Breschi MC, Blandizzi C, Del Taca M (2007) Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther 322(2): 435-442. doi: 10. 1124/jpet. 107. 122762.
14. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C (1998) An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 358(3): 261-268.
15. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Hasko G (1998) Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 125(2): 379-387. doi: 10. 1038/sj. bjp. 0702040.
16. Law WR (2006) Adenosine receptors in the response to sepsis: what do receptor-specific knockouts tell us? Am J Physiol Regul Integr Comp Physiol 291(4): R957-R958. doi: 10. 1152/ajpregu. 00412. 2006.
17. Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D, Reibman J, Li M, Jiang CK, Hirschhorn R, Recht PA, Ostad E, Levin RI, Cronstein BN (1997) Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med 186(9): 1615-1620.
18. Eltzschig HK (2009) Adenosine: an old drug newly discovered. Anesthesiology 111(4): 904-915. doi: 10. 1097/ALN. 0b013e3181b060f2.
19. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L, Lohinai Z, Southan GJ, Salzman AL, Szabo C (2000) Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 164(2): 1013-1019.
20. Gomez G, Sitkovsky MV (2003) Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 102(13): 4472-4478. doi: 10. 1182/blood-2002-11-36242002-11-3624.
21. Rahimian R, Fakhfouri G, Daneshmand A, Mohammadi H, Bahremand A, Rasouli MR, Mousavizadeh K, Dehpour AR (2010) Adenosine A(2A) receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats. Eur J Pharmacol 649(1-3): 376-381. doi: 10. 1016/j. ejphar. 2010. 09. 044.
22. Linden J (2006) New insights into the regulation of inflammation by adenosine. J Clin Invest 116(7): 1835-1837. doi: 10. 1172/JCI29125.
23. Henriques MG, Rae GA, Cordeiro RS, Williams TJ (1992) Endothelin-1 inhibits PAF-induced paw oedema and pleurisy in the mouse. Br J Pharmacol 106(3): 579-582.
24. Saleh TS, Calixto JB, Medeiros YS (1996) Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy. Br J Pharmacol 118(3): 811-819.
25. Moroney MA, Alcaraz MJ, Forder RA, Carey F, Hoult JR (1988) Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. J Pharm Pharmacol 40(11): 787-792.
26. Moore AR (2003) Pleural models of inflammation: immune and nonimmune. Methods Mol Biol 225: 123-128. doi: 10. 1385/1-59259-374-7: 123.
27. Lo TN, Almeida AP, Beaven MA (1982) Dextran and carrageenan evoke different inflammatory responses in rat with respect to composition of infiltrates and effect of indomethacin. J Pharmacol Exp Ther 221(1): 261-267.
28. Menegazzi M, Di Paola R, Mazzon E, Genovese T, Crisafulli C, Dal Bosco M, Zou Z, Suzuki H, Cuzzocrea S (2008) Glycyrrhizin attenuates the development of carrageenan-induced lung injury in mice. Pharmacol Res 58(1): 22-31. doi: 10. 1016/j. phrs. 2008. 05. 012.
29. Tomlinson A, Appleton I, Moore AR, Gilroy DW, Willis D, Mitchell JA, Willoughby DA (1994) Cyclo-oxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. Br J Pharmacol 113(3): 693-698.
30. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A (2008) Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 153(Suppl 1): S457-S464. doi: 10. 1038/bjp. 2008. 23.
31. Liaudet L, Pacher P, Mabley JG, Virag L, Soriano FG, Hasko G, Szabo C (2002) Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med 165(3): 372-377.
32. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA (1994) Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153(9): 4159-4168.
33. Hasko G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7(9): 759-770. doi: 10. 1038/nrd2638.
34. Linden J (2001) Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775-787. doi: 10. 1146/annurev. pharmtox. 41. 1. 775.
35. Eltzschig HK, Carmeliet P (2011) Hypoxia and inflammation. N Engl J Med 364(7): 656-665. doi: 10. 1056/NEJMra0910283.
36. Eltzschig HK, Eckle T (2011) Ischemia and reperfusion-from mechanism to translation. Nat Med 17(11): 1391-1401. doi: 10. 1038/nm. 2507.
37. Modis K, Gero D, Nagy N, Szoleczky P, Toth ZD, Szabo C (2009) Cytoprotective effects of adenosine and inosine in an in vitro model of acute tubular necrosis. Br J Pharmacol 158(6): 1565-1578. doi: 10. 1111/j. 1476-5381. 2009. 00432. x.
38. Trams EG, Lauter CJ (1974) On the sidedness of plasma membrane enzymes. Biochim Biophys Acta 345(2): 180-197.
39. Spicuzza L, Di Maria G, Polosa R (2006) Adenosine in the airways: implications and applications. Eur J Pharmacol 533(1-3): 77-88. doi: 10. 1016/j. ejphar. 2005. 12. 056.
40. Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK (2007) Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol 27(5): 1004-1013. doi: 10. 1161/ATVBAHA. 106. 126714.
41. Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, Odegard KC, Laussen PC, Thompson LF, Colgan SP (2006) Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood 108(5): 1602-1610. doi: 10. 1182/blood-2006-02-001016.
42. Revan S, Montesinos MC, Naime D, Landau S, Cronstein BN (1996) Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J Biol Chem 271(29): 17114-17118.
43. Lappas CM, Sullivan GW, Linden J (2005) Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 14(7): 797-806. doi: 10. 1517/13543784. 14. 7. 797.
44. Murphree LJ, Sullivan GW, Marshall MA, Linden J (2005) Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction. Biochem J 391(Pt 3): 575-580. doi: 10. 1042/BJ20050888.
45. Liaudet L, Mabley JG, Soriano FG, Pacher P, Marton A, Hasko G, Szabo C (2001) Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 164(7): 1213-1220.
46. Mabley JG, Pacher P, Liaudet L, Soriano FG, Hasko G, Marton A, Szabo C, Salzman AL (2003) Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 284(1): G138-G144. doi: 10. 1152/ajpgi. 00060. 200200060. 2002.
47. Luscinskas FW, Ma S, Nusrat A, Parkos CA, Shaw SK (2002) The role of endothelial cell lateral junctions during leukocyte trafficking. Immunol Rev 186: 57-67.
48. Impellizzeri D, Di Paola R, Esposito E, Mazzon E, Paterniti I, Melani A, Bramanti P, Pedata F, Cuzzocrea S (2011) CGS 21680, an agonist of the adenosine (A(2A)) receptor, decreases acute lung inflammation. Eur J Pharmacol. doi: 10. 1016/j. ejphar. 2011. 06. 049.
49. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Muller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 63(1): 1-34. doi: 10. 1124/pr. 110. 003285.
50. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K (2006) The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116(7): 1913-1923. doi: 10. 1172/JCI27933.
51. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK (2008) A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111(4): 2024-2035. doi: 10. 1182/blood-2007-10-117044.
52. Eckle T, Grenz A, Laucher S, Eltzschig HK (2008) A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118(10): 3301-3315. doi: 10. 1172/JCI34203.
53. Kroegel C, Antony VB (1997) Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J Off J Eur Soc Clin Respir Physiol 10(10): 2411-2418.
54. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D'Acquisto F, Di Rosa M (2000) Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292(1): 156-163.
55. Frode TS, Souza GE, Calixto JB (2001) The modulatory role played by TNF-alpha and IL-1 beta in the inflammatory responses induced by carrageenan in the mouse model of pleurisy. Cytokine 13(3): 162-168. doi: 10. 1006/cyto. 2000. 0816S1043-4666(00)90816-0.
56. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25(6): 280-288. doi: 10. 1016/j. it. 2004. 03. 008S1471490604001000.
57. Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6(4): 232-241. doi: 10. 1038/nrrheum. 2010. 4.
58. Kreckler LM, Wan TC, Ge ZD, Auchampach JA (2006) Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 317(1): 172-180. doi: 10. 1124/jpet. 105. 096016.
59. Sitkovsky MV (2003) Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 65(4): 493-501.